Detalhe da pesquisa
1.
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Cancer;
130(11): 1940-1951, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38288862
2.
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
J Am Acad Dermatol;
78(5): 863-871.e11, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29353026
3.
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
Liver Int;
35(1): 108-19, 2015 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24517252
4.
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.
Clin Cancer Res;
27(19): 5225-5235, 2021 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34158360
5.
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
PLoS One;
11(1): e0145409, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26752189
6.
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Hepatol Int;
10(3): 478-87, 2016 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26886127
7.
Association of four DNA polymorphisms with acute rejection after kidney transplantation.
Transpl Int;
21(9): 879-91, 2008 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18444945